Literature DB >> 30989234

TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters.

Sunil S Badve, Yesim Gökmen-Polar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30989234      PMCID： PMC6855961          DOI： 10.1093/jnci/djz052

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  19 in total

1.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

Review 2.  Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

Authors:  Ana C Garrido-Castro; Nancy U Lin; Kornelia Polyak
Journal:  Cancer Discov       Date:  2019-01-24       Impact factor: 39.397

Review 3.  Estrogen receptor beta in breast cancer.

Authors:  C Palmieri; G J Cheng; S Saji; M Zelada-Hedman; A Wärri; Z Weihua; S Van Noorden; T Wahlstrom; R C Coombes; M Warner; J-A Gustafsson
Journal:  Endocr Relat Cancer       Date:  2002-03       Impact factor: 5.678

4.  Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

Authors:  Sofia K Gruvberger-Saal; Pär-Ola Bendahl; Lao H Saal; Mervi Laakso; Cecilia Hegardt; Patrik Edén; Carsten Peterson; Per Malmström; Jorma Isola; Ake Borg; Mårten Fernö
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 5.  Estrogen receptor-beta and breast cancer: translating biology into clinical practice.

Authors:  Yuet-Kin Leung; Ming-Tsung Lee; Hung-Ming Lam; Pheruza Tarapore; Shuk-Mei Ho
Journal:  Steroids       Date:  2012-03-29       Impact factor: 2.668

6.  The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events.

Authors:  Claude C Warzecha; Shihao Shen; Yi Xing; Russ P Carstens
Journal:  RNA Biol       Date:  2009-11-22       Impact factor: 4.652

Review 7.  Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.

Authors:  George P Skliris; Etienne Leygue; Peter H Watson; Leigh C Murphy
Journal:  J Steroid Biochem Mol Biol       Date:  2007-12-08       Impact factor: 4.292

Review 8.  Protein mislocalization: mechanisms, functions and clinical applications in cancer.

Authors:  Xiaohong Wang; Shulin Li
Journal:  Biochim Biophys Acta       Date:  2014-04-04

Review 9.  Mutant p53 partners in crime.

Authors:  Michael P Kim; Guillermina Lozano
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

10.  TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Authors:  Utpal K Mukhopadhyay; Chetan C Oturkar; Christina Adams; Nadi Wickramasekera; Sanjay Bansal; Rajesh Medisetty; Austin Miller; Wendy M Swetzig; Laxmi Silwal-Pandit; Anne-Lise Børresen-Dale; Chad J Creighton; Jun Hyoung Park; Santhi D Konduri; Alka Mukhopadhyay; Alexander Caradori; Angela Omilian; Wiam Bshara; Benny Abraham Kaipparettu; Gokul M Das
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 11.816
View more
  1 in total

1.  CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer.

Authors:  Kelly E Craven; Yesim Gökmen-Polar; Sunil S Badve
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.